Cholera Toxin Subunit B as Adjuvant--An Accelerator in Protective Immunity and a Break in Autoimmunity

Vaccines
Thomas Stratmann

Abstract

Cholera toxin subunit B (CTB) is the nontoxic portion of cholera toxin. Its affinity to the monosialotetrahexosylganglioside (GM1) that is broadly distributed in a variety of cell types including epithelial cells of the gut and antigen presenting cells, macrophages, dendritic cells, and B cells, allows its optimal access to the immune system. CTB can easily be expressed on its own in a variety of organisms, and several approaches can be used to couple it to antigens, either by genetic fusion or by chemical manipulation, leading to strongly enhanced immune responses to the antigens. In autoimmune diseases, CTB has the capacity to evoke regulatory responses and to thereby dampen autoimmune responses, in several but not all animal models. It remains to be seen whether the latter approach translates to success in the clinic, however, the versatility of CTB to manipulate immune responses in either direction makes this protein a promising adjuvant for vaccine development.

References

Jun 1, 1973·Journal of General Microbiology·I Lönnroth, J Holmgren
Dec 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·T R HirstJ Holmgren
Feb 1, 1994·Protein Science : a Publication of the Protein Society·E A MerrittW G Hol
Apr 1, 1994·FEMS Microbiology Letters·M Lebens, J Holmgren
Mar 31, 1998·Journal of Immunological Methods·S LiljeqvistM Murby
Jul 17, 1999·Brain Research. Developmental Brain Research·D Kozireski-ChubackR W Ledeen
Aug 17, 2002·Protein Expression and Purification·Ana Paula de Mattos ArêasPaulo Lee Ho
Sep 7, 2004·Proceedings of the National Academy of Sciences of the United States of America·Nobuyuki MatobaTsafrir S Mor
Nov 23, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jia-Bin SunJan Holmgren
Jun 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·Tomonori NochiHiroshi Kiyono
Jun 20, 2008·Journal of Leukocyte Biology·Antonella D'AmbrosioMonica Boirivant
Dec 4, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jia-Bin SunJan Holmgren
Nov 3, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tomonori NochiHiroshi Kiyono
Jan 18, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jia-Bin SunJan Holmgren
Jun 4, 2013·Biological & Pharmaceutical Bulletin·Takahiro OkunoFumio Miake
Sep 17, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jia-Bin SunJan Holmgren

❮ Previous
Next ❯

Citations

Apr 5, 2016·Vaccines·Vasso Apostolopoulos
Jul 21, 2016·Human Vaccines & Immunotherapeutics·Miaoge XueNingshao Xia
Apr 16, 2017·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Mahdiye SaadiHamid Reza Nouri
Feb 12, 2017·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Beatriz MezaCarlos Angulo
Jul 19, 2019·Clinical and Experimental Immunology·R R C New
Dec 8, 2017·Journal of Cellular Physiology·Milica VujicicStanislava Stosic-Grujicic
Nov 9, 2018·Frontiers in Immunology·Franziska VoßSven Hammerschmidt
Oct 11, 2017·Biochemistry. Biokhimii︠a︡·E V NavolotskayaV P Zav'yalov
Feb 19, 2017·Cold Spring Harbor Perspectives in Biology·Maria Daniela Garcia-CastilloWayne I Lencer
Feb 19, 2019·Frontiers in Immunology·Aloysious SsemagandaMichael F Good
Sep 4, 2020·Advanced Materials·Chao PanHengliang Wang
Dec 6, 2020·BMC Molecular and Cell Biology·Davod JafariMohammad Morad Farajollahi
Mar 7, 2020·Biomaterials·Sean H KellyJoel H Collier
Mar 17, 2021·Expert Review of Vaccines·Yizhi Qi, Christopher B Fox
Jul 11, 2021·Scientific Reports·Srijita BasakAnurag P Srivastava
Jul 20, 2021·Advanced Drug Delivery Reviews·Chao PanHeng-Liang Wang
Aug 11, 2021·Pharmaceutics·Mohammad O FaruckIstvan Toth
Dec 22, 2020·ACS Pharmacology & Translational Science·Neeraj KumarRamesh Chandra
Dec 25, 2019·Journal of Chemical Information and Modeling·Neeraj KumarRamesh Chandra
Nov 4, 2021·Journal of Cellular Biochemistry·Debashrito DebAnurag P Srivastava

❮ Previous
Next ❯

Methods Mentioned

BETA
size exclusion chromatography
glycosylation
ELISA

Related Concepts

Related Feeds

Autoimmune Disease Therapy

In autoimmune diseases, the immune system responds and attacks self-antigens and damages or impairs the function of the tissues. The treatment for autoimmune diseases often involves immunosuppressive agents, but newer treatments are being investigated. Discover the latest research on autoimmune disease therapy here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.